Spina Bifida: Stem Cell Therapy Shows Promise in Fetal Surgery Trial

A promising recent approach combining fetal surgery with stem cell therapy is offering hope for babies diagnosed with spina bifida, a serious birth defect. Recent research, published in The Lancet on February 28, 2026, suggests this method is both safe and potentially effective in improving outcomes for infants with the most severe form of the condition, myelomeningocele.

Spina bifida occurs when the spinal column doesn’t close completely during pregnancy. This can lead to a range of disabilities, including paralysis, bowel and bladder control issues, and cognitive difficulties. Currently, surgical intervention during pregnancy is offered to close the opening in the spine, reducing some complications but not always preventing neurological problems. The new research builds on this existing treatment by adding a layer of cellular support.

How the New Therapy Works

Researchers, led by Dr. Diana Farmer at the University of California Davis Health, are applying stem cells – specifically mesenchymal stem cells derived from the mother’s placenta – directly to the fetal spinal cord during the corrective surgery. These cells are known for their ability to reduce inflammation, promote healing, and protect nerve tissue. The idea is to enhance the repair process and minimize long-term neurological damage.

In the initial phase 1 trial, six babies diagnosed with myelomeningocele received this combined treatment between July 2021 and December 2022. The surgical repair of the spinal column was successful in all cases, and importantly, none of the infants showed signs of infection or adverse effects related to the stem cell therapy. Further, imaging scans revealed that brain abnormalities often associated with spina bifida – specifically, a condition called posterior brain herniation – appeared to be reversed in all cases.

Long-Term Follow-Up is Key

While the initial results are encouraging, researchers emphasize that long-term follow-up is crucial. The children are currently being monitored regularly, and this monitoring will continue until they reach six years of age, to assess the therapy’s impact on their mobility, overall health, and quality of life. This extended observation period is essential to determine whether the benefits observed in infancy persist over time.

Spina Bifida: Understanding the Condition and Current Approaches

Spina bifida affects between 2 and 5 pregnancies per 10,000, and can often be detected during the second trimester ultrasound, typically around the 22nd week of pregnancy. In France, over 95% of cases are detected, a rate that is remarkably high compared to global averages, according to Jean-Marie Jouannic, head of the fetal medicine department at Trousseau Hospital in Paris.

Currently, most parents, after receiving comprehensive prenatal counseling, opt for surgical intervention during pregnancy to close the spinal opening. While this surgery reduces certain complications, it doesn’t eliminate all neurological issues. Here’s where the potential of stem cell therapy comes into play, offering a way to potentially improve outcomes beyond what surgery alone can achieve.

The Role of Placental Stem Cells

The use of stem cells derived from the placenta is a significant aspect of this new therapy. Placental stem cells are readily available, reducing the demand for potentially more complex or ethically challenging stem cell sources. They as well possess properties that make them well-suited for promoting tissue repair and reducing inflammation – key factors in addressing the damage caused by spina bifida.

What Does This Mean for the Future?

Dr. Farmer has expressed optimism that this experimental therapy could grow the standard of care for spina bifida treatment before birth. “If this allows more children to walk who wouldn’t have, it would become their standard of care,” she stated. The results are generating excitement within the medical community and opening doors to potential new treatments for spina bifida and other congenital malformations.

Further clinical trials, involving larger groups of patients and longer follow-up periods, are underway to refine the surgical techniques and treatment protocols. These trials will be critical in confirming the safety and efficacy of this innovative approach and determining its potential to improve the lives of children born with spina bifida. The ongoing research will also help to identify which patients are most likely to benefit from the therapy and to optimize the dosage and timing of stem cell administration.

The development of this therapy represents a significant step forward in the treatment of spina bifida, offering a new avenue of hope for families affected by this challenging condition. As research continues and our understanding of stem cell therapy grows, we can anticipate even more advancements in the field of fetal medicine and congenital defect treatment.